Method for constructing fingerprint spectrum of Xihuang capsule and fingerprint spectrum

Abstract

To accurately, clearly and objectively evaluate the quality of Xihuang capsules.SOLUTION: A fingerprint spectrum construction method for Xihuang capsules and a fingerprint spectrum are disclosed which include: a step S1 of collecting contents of a Xihuang capsule, adding a methanol-chloroform-phosphoric acid solution, and carrying out ultrasonic extraction to obtain a Xihuang capsule test solution; a step S2 of dissolving cholic acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, muscone, and myrrhone in ethanol to obtain a mixed standard solution 1; dissolving bitter lignan, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandaracopimaric acid in methanol to obtain a mixed standard solution 2; a step S3 of carrying out respective chromatogram analyses of the Xihuang capsule test solution and the mixed standard solutions 1 and 2, and recording corresponding chromatograms; and a step S4 of constructing a fingerprint spectrum of the Xihuang capsule according to the chromatogram of the Xihuang capsule test solution and the chromatograms of the mixed standard solutions 1 and 2.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention belongs to the technical field of quality control management of composite traditional Chinese medicine preparations, and specifically relates to a method for constructing a fingerprint spectrum of Xihuang Capsule and the fingerprint spectrum. [Background technology]

[0002] Xihuang Capsule originates from the ancient Xihuang medicine in the "Complete Collection of Medical Treatments" by Wang Hongxu, a famous doctor in the Qing Dynasty, and is made by modern technology by refining four Chinese herbal medicines: Cow Gallbladder, Musk, Frankincense, and Myrrh. In the prescription, Cow Gallbladder is the main medicine that purifies the mind, suppresses heat and phlegm, opens acupuncture points, relieves swelling, complements the aromatic and spicy properties of musk, opens meridians and channels, disperses blood and relieves swelling, Frankincense and other medicines cooperate with each other to activate blood circulation, relieve blood circulation, relieve swelling, and relieve pain. The whole prescription cooperates with each other to remove heat and toxins, activate blood circulation, remove blood circulation, and relieve stiff swelling. At present, in clinical practice, it is commonly used to treat breast fibroma, breast cancer, cervical lymph node tuberculosis, lymphadenitis, osteomyelitis, appendicitis, suppurative dermatitis, multiple abscesses, bacteremia, acute suppurative infections, malignant tumors, etc. After many years of clinical application, it has remarkable efficacy, is safe and reliable, has a wide anti-tumor spectrum, and is the first choice drug for the treatment of tumors, proliferative diseases and infectious diseases, and is known as "China's national anti-cancer drug".

[0003] Currently, there are few quality inspection methods for Xihuang Capsules, and most of them are composition studies of single drugs in the prescription, which cannot reflect the overall composition information of Xihuang Capsules, so its quality cannot be well controlled. Summary of the Invention

[0004] The objective of the present invention is to solve the shortcomings of the prior art and provide a method for constructing a fingerprint spectrum of Xihuang Capsule and a fingerprint spectrum, which can accurately, clearly and objectively evaluate the quality of Xihuang Capsule, and is of important action and value to the quality control and improvement of Xihuang Capsule and the improvement of its clinical efficacy.

[0005] The present invention is achieved by the following technical solutions:

[0006] The construction method of the fingerprint spectrum of Xihuang capsule is as follows: S1, taking the content of Xihuang Capsule, adding methanol-chloroform-phosphoric acid solution, and extracting by ultrasonic wave to obtain the test solution of Xihuang Capsule; S2, dissolving bile acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone and myrrh ketone in ethanol to obtain mixed standard solution 1, and dissolving bitter lignan (quassin), 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetyl-boswellic acid, acetyl-11α-methoxy-β-boswellic acid and sandaracopimaric acid in methanol to obtain mixed standard solution 2; S3, injecting the test solution of Xihuang capsule, the mixed standard solution 1 and the mixed standard solution 2 into a high performance liquid chromatography to perform chromatographic analysis, and recording the corresponding chromatograms; S4 includes a step of constructing a fingerprint spectrum of Xihuang Capsule based on the chromatogram of the Xihuang Capsule test solution obtained in S3 and the chromatograms of the mixed standard solution 1 and the mixed standard solution 2.

[0007] Preferably, in S1, in the methanol-chloroform-phosphoric acid solution, the volume ratio of methanol to chloroform is 1:3, and the volume ratio of the total amount of methanol and chloroform to phosphoric acid is 100:0.2.

[0008] Preferably, in S3, the column used for high performance liquid chromatography is Hypersil C18 ODS.

[0009] Preferably, in S3, the mobile phase used for the chromatographic analysis is methanol-0.08% phosphoric acid-acetonitrile.

[0010] Furthermore, in S3, the chromatographic analysis uses a UV-visible absorption detector with multi-wavelength switching detection, with detection wavelengths: 0-15 min: 254 nm, 15-45 min: 249 nm, 45-90 min: 239 nm, 90-110 min: 210 nm.

[0011] Furthermore, in S3, during chromatographic analysis, the gradient elution procedure was: 0-15 min methanol volume 54% → 65%, 0.08% phosphoric acid volume 36% → 25%, 15-45 min methanol volume 65% → 78%, 0.08% phosphoric acid volume 25% → 12%, 45-55 min methanol volume 78% → 80%, 0.08% phosphoric acid volume 12% → 10%, 55-65 min methanol volume 80% → 82%, 0. 0.08% phosphoric acid volume 10% → 8%, 65~75min methanol volume 82% → 84%, 0.08% phosphoric acid volume 8% → 6%, 75~90min methanol volume 84% → 86%, 0.08% phosphoric acid volume 6% → 4%, 90~100min methanol volume 86% → 88%, 0.08% phosphoric acid volume 4% → 2%, 100~110min methanol volume 88% → 90%, 0.08% phosphoric acid volume 2% → 0%.

[0012] Preferably, S4 specifically introduces the chromatograms of different batches of Xihuang Capsule test liquid into the Chinese medicine chromatogram fingerprint spectrum similarity evaluation system 2004A, selects the chromatographic peaks existing in the chromatograms of different batches of Xihuang Capsule as common peaks, generates a control fingerprint spectrum of Xihuang Capsule using an average calculation method, calculates the relative retention time and relative peak area of ​​each common peak, labels the chemical components of each common peak in the control fingerprint spectrum according to the retention times of the chromatograms of the mixed standard solution 1 and the mixed standard solution 2, and uses the control fingerprint spectrum R to generate a common chromatographic peak pattern, and analyzes and calculates the similarity between the chromatograms of each batch of Xihuang Capsule and the common chromatographic peaks to confirm the reliability of the chromatograms of each batch of Xihuang Capsule test liquid;

[0013] The chromatogram of the Xihuang Capsule test solution obtained in S3 is compared with the chromatograms of mixed standard solution 1 and mixed standard solution 2, and the chromatogram identifies peak 3 as myrrh ketone, peak 4 as sandaracopimaric acid, peak 8 as bitter lignan, peak 10 as musk ketone, peak 11 as 11-carbonyloxy-β-boswellic acid, peak 12 as 11-carbonyloxy-β-acetylboswellic acid, and peak 13 as acetyl-11α-methoxy-β-boswellic acid, and the Xihuang Capsule fingerprint spectrum is obtained.

[0014] 1 is a fingerprint spectrum of Xihuang capsule constructed by the above method. Effect of the Invention

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] Chinese herbal medicine fingerprint spectrum can characterize the main chemical components of medicines in a comprehensive and macroscopic way, and is currently recognized as one of the most suitable means for the quality control of chemical components of Chinese herbal medicines and Chinese patent medicines. The Chinese herbal medicine fingerprint spectrum combined with modern analytical technology can use the chemical group that embodies the medicinal substance basis of Chinese herbal medicines to comprehensively evaluate the quality of Chinese herbal medicines, and is widely used in the formulation of Chinese herbal medicine quality standards. Based on this, the present invention provides a method for constructing Xihuang capsule fingerprint spectrum, the present invention carries out experimental investigations on different extraction methods and extraction solvents, optimizes the extraction method and solvent, obtains more chromatographic information, and has high component content. The high performance liquid chromatography fingerprint spectrum detection method provided by the present invention has good system adaptability, high specificity, high accuracy, good stability, and high reproducibility, meets the fingerprint spectrum construction requirements, is safer and more efficient in the quality control of Xihuang capsule clinical drugs, and can better ensure safety and efficacy, and can be applied to the quality control of Xihuang capsule, which is of great significance to the component identification, quality evaluation and formulation of quality standard of Xihuang capsule. The fingerprint spectrum of Xihuang Capsule constructed by the method provided by the present invention has a total of 13 common characteristic peaks, and 7 characteristic peaks are identified, which can characterize the quality of Xihuang Capsule and objectively reflect the order and interrelationship of each fingerprint characteristic peak, focus on the overall appearance of the characteristics, and not only avoid the one-sided determination of Xihuang Capsule quality from individual chemical components, but also reduce the possibility of artificial processing for quality. [Brief description of the drawings]

[0017] [Figure 1] 1 is a chromatogram of mixed standard 1 of the present invention. [Diagram 2] Chromatogram of mixed standard 2 of the present invention. [Diagram 3] 1 is a fingerprint spectrum of test samples of 11 batches of Xihuang capsules of the present invention. [Figure 4] 1 is a mass spectrum of a control myrrh ketone of the present invention. [Diagram 5] 1 is a mass spectrum of a control sample of sandaracopimaric acid according to the present invention. [Figure 6] 1 is a mass spectrum of a bitter lignan control sample of the present invention. [Figure 7] 1 is a mass spectrum of a control musk ketone of the present invention. [Figure 8] 1 is a mass spectrum of a control sample of 11-carbonyloxy-β-boswellic acid according to the present invention. [Figure 9] 1 is a mass spectrum of a control sample of 11-carbonyloxy-β-acetylboswellic acid according to the present invention. [Figure 10] 1 is a mass spectrum of a control sample of acetyl-11α-methoxy-β-boswellic acid according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] In order to better understand the present invention, the present invention will now be described in conjunction with examples, which are merely intended to further illustrate the features and advantages of the present invention and are not intended to limit the scope of the claims of the present invention.

[0019] 1. The method for constructing the fingerprint spectrum of Xihuang capsule includes the following steps:

[0020] S1, Preparation of Xihuang Capsule Test Solution: The contents of different batches of Xihuang Capsules were accurately weighed and placed into a stoppered conical flask, and then methanol-chloroform-phosphoric acid solution was added, followed by ultrasonic extraction. The filtrate was then filtered through a 0.45 μm microporous membrane to obtain the test solution of Xihuang Capsules.

[0021] S2, Preparation of standard solutions: Accurately weigh bile acids, butadeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, and myrrh ketone, place them in a measuring flask, and fill to the mark with ethanol to obtain mixed standard solution 1. Accurately weigh bitter lignans, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandaracopimaric acid, place them in a measuring flask, fill to the mark with methanol, shake well, and obtain mixed standard solution 2.

[0022] Accurately aspirate the test solution S3 and the mixed standard solution 1 and mixed standard solution 2 of S2, respectively, and inject them into the high performance liquid chromatography, and record the chromatogram.

[0023] S4, the chromatogram of the Xihuang Capsule test liquid obtained in S3 is derived and introduced into the Chinese medicine chromatogram fingerprint spectrum similarity evaluation system 2004A, the chromatographic peaks existing in the chromatograms of different batches of Xihuang Capsule are selected as common peaks, and there are 13 common peaks, the average value calculation method is used to generate the control fingerprint spectrum of Xihuang Capsule, the relative retention time and relative peak area of ​​each common peak are calculated, the chemical components of the peaks in the control fingerprint spectrum are labeled based on the retention times of the chromatograms of mixed standard solution 1 and mixed standard solution 2, and the control fingerprint spectrum R is used to generate a common chromatographic peak pattern, the similarity between the chromatograms of each batch of Xihuang Capsule and the common chromatographic peaks is analyzed and calculated, and the reliability of the chromatograms of each batch of Xihuang Capsule test liquid is confirmed.

[0024] The chromatogram of the Xihuang Capsule test solution obtained in S5 and S3 is compared with the chromatograms of mixed standard solution 1 and mixed standard solution 2, and in the Xihuang Capsule spectrum, peak 3 is identified as myrrh ketone, peak 4 is sandaracopimaric acid, peak 8 is bitter lignan, peak 10 is musk ketone, peak 11 is 11-carbonyloxy-β-boswellic acid, peak 12 is 11-carbonyloxy-β-acetylboswellic acid, and peak 13 is acetyl-11α-methoxy-β-boswellic acid, and the fingerprint spectrum of Xihuang Capsule is obtained.

[0025] Of these, the method for preparing the test solution for Xiongxiang Capsules in S1 is preferably to accurately weigh 240 mg of the contents of 11 batches of Xiongxiang Capsules, place them in a 250 mL stoppered conical flask, add 100 mL of [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution, extract with ultrasound for 30 minutes, and filter the filtrate through a 0.45 μm microporous membrane to obtain the test solution.

[0026] The method for preparing the standard solutions in S2 is to accurately weigh bile acid, butadeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, and myrrh ketone, place them in a measuring flask, and measure up to the mark with ethanol to obtain mixed standard solution 1; accurately weigh bitter lignan, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandaracopimaric acid, place them in a measuring flask, measure up to the mark with methanol, shake well, and obtain mixed standard solution 2; the prepared mixed standard solution It is preferable that the concentrations of bile acids, butadeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, myrrh ketone, bitter lignan, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandaracopimaric acid in the solution are 200 μg / mL, 200 μg / mL, 200 μg / mL, 40 μg / mL, 150 μg / mL, 150 μg / mL, 100 μg / mL, 100 μg / mL, 100 μg / mL, and 150 μg / mL, respectively.

[0027] The liquid phase chromatogram conditions in S3 were as follows: column: Hypersil C18 ODS (4.6 x 250 mm x 5 μm), mobile phase: methanol (A)-0.08% phosphoric acid (B)-acetonitrile (C), gradient elution, UV-visible absorption detector multi-wavelength switching detection, detection wavelengths: 0-15 min: 254 nm, 15-45 min: 249 nm, 45-90 min: 239 nm, 90-110 min: 210 nm, column temperature: 27°C, flow rate: 0.6 mL / min, injection volume: 20 μL, elution procedure is shown in Table 1 below.

[0028] [Table 1]

[0029] 2. Optimization process of fingerprint spectrum detection:

[0030] S1, Optimization of sample solution preparation:

[0031] The present invention adopts ultrasonic extraction method because, as a result of experimental investigation by different extraction methods (ultrasonic, reflux, immersion), the spectral components obtained by ultrasonic extraction are more comprehensive and have better separation ability.

[0032] In the present invention, the extraction effects of different extraction solvents ([acetonitrile-chloroform (1:3)]-phosphoric acid (100:0.2) solution, methanol-chloroform (1:3) solution, and [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution) were compared, and it was found that when [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution was used as the extraction solvent, the extract had the largest amount of chromatogram information and the highest component content, so [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution was selected for extraction.

[0033] S2, Optimization of chromatographic conditions:

[0034] In the present invention, the detection wavelengths are investigated by an ultraviolet-visible absorption detector, and chromatograms at 254 nm, 249 nm, 239 nm, and 210 nm are extracted. When the detection wavelength conditions are: 0-15 min, 254 nm, 15-45 min, 249 nm, 45-90 min, 239 nm, 90-110 min, and 210 nm, the amount of information contained in the chromatogram is the most comprehensive and the baseline is the smoothest, so this method is selected as the detection wavelength condition.

[0035] In the present invention, flow rates (0.6 mL / min, 0.8 mL / min, 1.0 mL / min) were screened, and it was found that the peaks appeared best and the separation was the best when the flow rate was 0.6 mL / min, and the sustained flow rate was maintained at 0.6 mL / min.

[0036] In the present invention, the column temperatures (25°C, 27°C, 30°C) were screened, and the peaks appeared best when the column temperature was kept at 27°C, and the separation effect of each component was good. Therefore, the column temperature of 27°C was finally selected.

[0037] In the present invention, the elution effect under different gradients of several different elution systems, including methanol-water, acetonitrile-water, methanol-0.3% phosphoric acid-water, acetonitrile-0.1% phosphoric acid-water, methanol-0.1% phosphoric acid-acetonitrile, and methanol-0.08% phosphoric acid-acetonitrile, is compared. The results show that when methanol-0.08% phosphoric acid-acetonitrile is the mobile phase, the separation effect of each component in Xihuang Capsule is good, and finally methanol-0.08% phosphoric acid-acetonitrile is selected as the mobile phase.

[0038] After determining the optimal mobile phase composition, the present invention screens the optimal gradient elution procedure through a large number of experiments. The experimental results show that the following elution procedures are obtained: 0-15 min: 54% → 65% methanol volume, 36% → 25% 0.08% phosphoric acid volume; 15-45 min: 65% → 78% methanol volume, 25% → 12% 0.08% phosphoric acid volume; 45-55 min: 78% → 80% methanol volume, 12% → 10% 0.08% phosphoric acid volume; 55-65 min: 80% → 82% methanol volume, 10% 0.08% phosphoric acid volume. When adopting the following schedule: 65~75min methanol volume 82% → 84%, 0.08% phosphoric acid volume 8% → 6%, 75~90min methanol volume 84% → 86%, 0.08% phosphoric acid volume 6% → 4%, 90~100min methanol volume 86% → 88%, 0.08% phosphoric acid volume 4% → 2%, 100~110min methanol volume 88% → 90%, 0.08% phosphoric acid volume 2% → 0%, good separation of each chromatographic peak in the chromatogram can be achieved.

[0039] The present invention will be described in detail below with reference to examples. In the examples, unless specific conditions are given, the description will be given according to conventional conditions or manufacturer's recommended conditions. Unless the manufacturer is given, the reagents or equipment used are conventional products that can be purchased commercially.

[0040] The equipment and reagents used in the examples are as follows:

[0041] Experimental Equipment

[0042] 1. The equipment is shown in Table 2.

[0043] [Table 2]

[0044] 2. Chemicals and Reagents

[0045] The batch numbers of the 11 batches of Xihuang capsule samples are shown in Table 3 below.

[0046] [Table 3]

[0047] Controls: Bile acid control (batch no. LY0307), butadeoxycholic acid (batch no. LY0686), deoxycholic acid control (batch no. LY0306), bilirubin control (batch no. LY0305), musk ketone control (batch no. LY0810), myrrh ketone control (batch no. PCS1410), sandaracopimaric acid control (batch no. R19618), bitter lignan control (batch no. BTQ50940 0), 11-carbonyloxy-β-boswellic acid control sample (batch number LY0864), 11-carbonyloxy-β-acetylboswellic acid control sample (batch number DS1195), acetyl 11α-methoxy-β-boswellic acid control sample (batch number HA015687), all of the above control samples were purchased from China Food and Drug Inspection Institute, methanol (analytical purity), phosphoric acid (analytical purity), acetonitrile (chromatographic purity).

[0048] Example 1 The method for constructing the fingerprint spectrum of Xihuang capsule includes the following steps:

[0049] S1, Preparation of Xihuang Capsule Test Solution:

[0050] 240 mg of the contents of 11 batches of Xihuang capsules were placed in a 250 mL stoppered conical flask, 100 mL of [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution was added, and the mixture was extracted by ultrasonic for 30 min. The filtrate was then filtered through a 0.45 μm microporous membrane to obtain the test solution.

[0051] S2, Preparation of standard solutions:

[0052] Accurately weigh out bile acids, butadeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, and myrrh ketone, place them in a measuring flask, and measure up to the mark with ethanol to obtain mixed standard solution 1. Accurately weigh out bitter lignans, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandaracopimaric acid, place them in a measuring flask, measure up to the mark with methanol, shake well, and obtain mixed standard solution 2. The bile acids in the prepared mixed standard solutions were The concentrations of cholic acid, butadeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, myrrh ketone, bitter lignan, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandaracopimaric acid are 200 μg / mL, 200 μg / mL, 200 μg / mL, 40 μg / mL, 150 μg / mL, 150 μg / mL, 100 μg / mL, 100 μg / mL, 100 μg / mL, and 150 μg / mL, respectively.

[0053] S3, 11 batches of Xihuang capsule test solution and standard solution were accurately aspirated and injected into high performance liquid chromatography, and the chromatogram was recorded. The liquid phase chromatogram conditions were as follows: column: Hypersil C18 ODS (4.6 × 250 mm × 5 μm), mobile phase: methanol (A)-0.08% phosphoric acid (B)-acetonitrile (C), gradient elution, ultraviolet-visible absorption detector multi-wavelength switching detection, detection wavelength: 0-15 min: 254 nm, 15-45 min: 249 nm, 45-90 min: 239 nm, 90-110 min: 210 nm, column temperature: 27 ° C, flow rate 0.6 mL / min, injection volume: 20 μ L, elution procedure is shown in Table 1 below.

[0054] S4, the chromatograms of the 11 batches of Xihuang Capsule test liquid obtained in S3 are derived and introduced into the Chinese medicine chromatogram fingerprint spectrum similarity evaluation system 2004A, the chromatographic peaks present in the chromatograms of the 11 batches of Xihuang Capsule are selected as common peaks, the average value calculation method is used to generate the control fingerprint spectrum R of Xihuang Capsule, the relative retention time and relative peak area of ​​each common peak are calculated, and the chemical components of the peaks in the control fingerprint spectrum are labeled based on the retention time of the standard liquid chromatogram.

[0055] The chromatograms of the Xihuang Capsule test solution obtained in S5 and S3 (Figure 3) were compared with the standard solution chromatograms (Figures 1 and 2), and in conjunction with Figures 4 to 10, the main components were identified. The results of comparing the chromatographic peaks 3, 4, 8, 10, 11, 12, and 13 in Xihuang Capsule were: myrrh ketone (retention time 18.834 min), sandaracopimaric acid (retention time 22.316 min), bitter lignan (retention time 33.579 min), musk ketone (retention time 44.632 min), 11-carbonyloxy-β-boswellic acid (retention time 49.086 min), 11-carbonyloxy-β-acetylboswellic acid (retention time 53.643 min), and acetyl-11α-methoxy-β-boswellic acid (retention time 58.967 min), and the fingerprint spectrum of Xihuang Capsule was obtained.

[0056] At the same time, in the present invention, the automatically generated control fingerprint spectrum R is used to generate a common chromatographic peak pattern, and through analysis and calculation, it is found that there is a relatively good similarity between the common chromatographic peaks of 11 batches of Xihuang Capsules, which indicates that the fingerprint spectrum of Xihuang Capsule established by this method can well detect the quality of Xihuang Capsule and 11 batches of Xihuang Capsules, and the results are shown in Table 4.

[0057] [Table 4]

[0058] Example 2 Methodological considerations of the fingerprint spectrum detection method:

[0059] S1, Accuracy test

[0060] The standard solution prepared by the method of Example 1 was taken and analyzed according to the detection method of Example 1. Six parallel injections were performed, with the sample injection volume of 20 μL. The peak area and retention time were analyzed to calculate the RSD value. The results are shown in Table 5. It can be seen from the results that the parallel injection precision of this device is good.

[0061] [Table 5]

[0062] S2, stability test

[0063] 1.25g of the content of Xihuang Capsule was taken, and the test solution was prepared according to the method of Example 1. The test solution was analyzed according to the detection method of Example 1. It was injected and analyzed at different times of 0, 2, 6, 12, 18 and 24h. The sample injection volume was 20μL. Myrrh ketone, sandaracopimaric acid, bitter lignan, musk ketone, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, and acetyl-11α-methoxy-β-boswellic acid were used as the reference peaks. The RSD value was calculated by analyzing the peak area and retention time of the common peaks in the HPLC fingerprint spectrum of the sample. The results are shown in Table 6. It can be seen from the results that the chromatographic peaks of the Xihuang Capsule test solution showed little change within 24h and had good stability.

[0064] [Table 6]

[0065] S3, Reproducibility test

[0066] According to the test solution method in Example 1, 6 batches of sample solution were prepared. Referring to the chromatographic conditions of Example 1, the sample injection volume was 20 μL. Myrrh ketone, sandaracopimaric acid, bitter lignan, musk ketone, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, and acetyl-11α-methoxy-β-boswellic acid were used as reference peaks. The RSD value was calculated by analyzing the peak area and retention time of the common peaks in the HPLC fingerprint spectrum of the sample. The results are shown in Table 4. It can be seen from the results that the chromatographic peaks of the sample have good reproducibility, and the method has good reproducibility.

[0067] [Table 7]

[0068] As can be seen from the above experimental results, the method for constructing the fingerprint spectrum of Xihuang Capsule provided by the present invention has the characteristics of good stability, high accuracy and good reproducibility, which can comprehensively and objectively evaluate the quality of Xihuang Capsule and help ensure the quality of clinical efficacy.

[0069] The above embodiments are merely illustrative of the present invention and do not limit the present invention, and the scope of protection of the present invention is limited by the claims. The above content is merely an example and explanation of the idea of ​​the present invention, and various modifications, additions, or equivalent replacements made by those skilled in the art to the specific embodiments described herein are all within the scope of protection of the present invention as long as they do not deviate from the idea of ​​the present invention or exceed the scope defined by the claims.

Claims

1. S1: taking the content of Xiong Huang capsule, adding methanol-chloroform-phosphoric acid solution, and extracting by ultrasonic wave to obtain the test solution of Xiong Huang capsule; S2, dissolving bile acid, butadeoxycholic acid, deoxycholic acid, bilirubin, musk ketone and myrrh ketone in ethanol to obtain a mixed standard solution 1, and dissolving bitter lignan, 11-carbonyloxy-β-boswellic acid, 11-carbonyloxy-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid and sandaracopimaric acid in methanol to obtain a mixed standard solution 2; S3, injecting the Xihuang capsule test solution, the mixed standard solution 1 and the mixed standard solution 2 into a high performance liquid chromatography to perform chromatographic analysis, and record the corresponding chromatograms; A method for constructing a fingerprint spectrum of Saikou Capsule, comprising the steps of: (S4) constructing a fingerprint spectrum of Saikou Capsule based on the chromatogram of the Saikou Capsule test solution obtained in S3 and the chromatograms of mixed standard solution 1 and mixed standard solution 2.

2. The method for constructing a fingerprint spectrum of Xihuang Capsule as described in claim 1, characterized in that in S1, in the methanol-chloroform-phosphoric acid solution, the volume ratio of methanol to chloroform is 1:3, and the volume ratio of the total amount of methanol and chloroform to phosphoric acid is 100:0.

2.

3. The method for constructing a fingerprint spectrum of Xihuang Capsule as described in claim 1, characterized in that in S3, the column used for high performance liquid chromatography is Hypersil C18 ODS.

4. The method for constructing a fingerprint spectrum of Xihuang Capsule according to claim 1, characterized in that in S3, the mobile phase used for chromatographic analysis is methanol-0.08% phosphoric acid-acetonitrile.

5. The method for constructing a fingerprint spectrum of Xihuang Capsule as described in claim 4, characterized in that in S3, the chromatogram analysis uses an ultraviolet-visible absorption detector multi-wavelength switching detection, with detection wavelengths: 0-15 min: 254 nm, 15-45 min: 249 nm, 45-90 min: 239 nm, 90-110 min: 210 nm.

6. In S3, during chromatographic analysis, the gradient elution procedure was: 0-15 min, methanol volume 54% → 65%, 0.08% phosphoric acid volume 36% → 25%, 15-45 min, methanol volume 65% → 78%, 0.08% phosphoric acid volume 25% → 12%, 45-55 min, methanol volume 78% → 80%, 0.08% phosphoric acid volume 12% → 10%, 55-65 min, methanol volume 80% → 82%, 0.08% phosphoric acid volume 10% → 8%, 65-75 min, The method for constructing a fingerprint spectrum of Xihuang Capsule as described in claim 4, characterized in that: min methanol volume 82% → 84%, 0.08% phosphoric acid volume 8% → 6%, 75-90 min methanol volume 84% → 86%, 0.08% phosphoric acid volume 6% → 4%, 90-100 min methanol volume 86% → 88%, 0.08% phosphoric acid volume 4% → 2%, 100-110 min methanol volume 88% → 90%, 0.08% phosphoric acid volume 2% → 0%.

Images